Literature DB >> 16116136

Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.

Steven Vernino1, Diva R Salomao, Thomas M Habermann, Brian P O'Neill.   

Abstract

Mycophenolate mofetil (MM), an immunosuppressant used after organ transplantation, is also used for treatment of autoimmune myasthenia gravis (MG). A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. Primary CNS lymphoma regressed on withdrawal of MM. Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116136     DOI: 10.1212/01.wnl.0000173031.56429.04

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Myasthenia gravis developing in a patient with CNS lymphoma.

Authors:  Rami Masroujeh; Zaher K Otrock; Bassem Yamout; Mark N Jabbour; Ali Bazarbachi
Journal:  Int J Hematol       Date:  2010-02-09       Impact factor: 2.490

2.  Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.

Authors:  F Hanisch; M Wendt; S Zierz
Journal:  Eur J Med Res       Date:  2009-08-12       Impact factor: 2.175

3.  Renal cell carcinoma with proliferative lupus nephritis.

Authors:  Koh-Wei Wong
Journal:  BMJ Case Rep       Date:  2015-01-16

Review 4.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 5.  Idiopathic inflammatory myopathies: current and future therapeutic options.

Authors:  Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil.

Authors:  Brian Patrick O'Neill; Steven Vernino; Ahmet Dogan; Caterina Giannini
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

7.  [Myasthenia gravis].

Authors:  J Schodrowski; M Seipelt; I Adibi-Sedeh; C Eienbröker; B Tackenberg
Journal:  Internist (Berl)       Date:  2016-04       Impact factor: 0.743

Review 8.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

9.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

10.  Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Authors:  Chad Heatwole; Emma Ciafaloni
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.